Home  »  Stocks to Invest   »  Here’s the Reason Why the Worth of Chembio Diagn...

Here’s the Reason Why the Worth of Chembio Diagnostics, Inc. (CEMI) Stock is Increasing in Aftermarket

Chembio Diagnostics, Inc. (CEMI), a company that develops, manufactures, and commercializes point-of-care (POC) diagnostic tests, has surged 10.68% in aftermarket trading sessions. Consequently, CEMI stock is changing hands at $2.28 at the time of the writing. The increase could be attributed to the announcement of EUA application submission. On Tuesday, CEMI closed the day at $2.06 after increasing 1.48% during regular trading hours.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored

Why CEMI Increasing?

On Tuesday, CEMI announced the submission of the Emergency Use Authorization (EUA) application to US FDA for the new DPP SARS-CoV-2 Antigen test. Previously, the company received the award for Preparedness and Response, to assist in developing a COVID-19 point-of-care antigen test system from BARDA. DPP SARS-CoV-2 Antigen test system is designed in such a way that it could prove handy for detecting SARS-CoV-2 antigens in just 20 minutes. The antigen system is designed to use a minimally invading nasal swab and which could be read visually.

Q3 2021 Financial Results

On 4th November, CEMI reported the financial results for the third quarter of the fiscal year 2021. The quarter ended on 30th September 2021. The company generated total revenues of $12.05 million during the quarter against $10.27 million for the same period of 2020. The total costs and operating expenses for the period were $17.68 million against $4.90 million for the same period of 2020. The net loss suffered by the company during the period was $6.36 million (or $0.24 per basic and diluted share) against $5.53 million (or $0.28 per basic and diluted share) for the same period of 2020.

Executive Commentary

Richard Eberly, CEMI President, and Chief Executive Officer, while commenting on the results, said that the product revenue growth was mostly due to the largest purchase order in the company’s history. Besides, the company continues to address the labor issues and global supply chain hindrances to increase its production capacity. He further added that the company would continue to do everything to minimize the impact of continuing market challenges faced by the customers.

Future Outlook for CEMI

A closer look at statistics reveals CEMI stock hasn’t faced much volatility in the recent past. Analysts suggest that a continuous improvement in the financial stature of the company, as depicted in quarterly results, is the vanguard for the upcoming success of CEMI stock. Hence, potential investors should keep a close eye on CEMI stock fluctuations.

Leave a Comment

Your email address will not be published. Required fields are marked *

Related Posts

385

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

The 5 Best Inflation Stocks for 2022

100% free. stop anytime no spam

Get our free report on the stocks that we recommend for investors who want to protect their portfolios from inflation.

Receive Best Stock To Trade Before The Opening Bell

 

 

100% Free. Stop Anytime. No Spam